Steve Stryker
About Steve Stryker
Steve Stryker is a Senior Research Scientist at Bristol Myers Squibb in Princeton, NJ, with over 30 years of experience in preclinical safety and investigational toxicology.
Current Role at Bristol Myers Squibb
Steve Stryker currently serves as a Senior Research Scientist at Bristol Myers Squibb, located in Princeton, NJ. In his role, he coordinates and directs in vivo investigational toxicology studies and metabolomic studies, contributing to the company's ongoing research and development efforts in preclinical safety.
Previous Employment at Johnson & Johnson
Steve Stryker worked at Johnson & Johnson and its subsidiaries for a combined total of 14 years. From 1990 to 2002, he served at Johnson & Johnson PRD as a Scientist, later working at Johnson & Johnson/Ethicon from 2003 to 2004 as a Research Scientist. During his time at these companies, he focused on preclinical safety, contributing to research in discovery toxicology and surgical/medical devices.
Experience at Overlook Hospital and Huntingdon Life Sciences
Steve Stryker has also gained valuable experience in preclinical safety through his roles at Overlook Hospital and Huntingdon Life Sciences. He served as a Pathologists' Assistant at Overlook Hospital from 1989 to 1990. Prior to that, from 1986 to 1989, he worked at Huntingdon Life Sciences as an Associate Supervisor Necropsy, where he honed his expertise in necropsy procedures and safety assessments.
Educational Background
Steve Stryker holds a Bachelor of Arts degree in Biology from The King's College, where he studied from 1982 to 1986. His educational foundation in biology laid the groundwork for his extensive career in preclinical safety and toxicology, enabling him to contribute effectively to various research roles throughout his professional journey.
Specializations and Research Focus
With over 30 years of experience, Steve Stryker specializes in in vivo investigational toxicology and preclinical safety assessment for surgical and medical devices. He has been involved in investigational metabolomics and transcriptomics studies, serving as both a bench scientist and a Study Director for GLP and Non-GLP studies. His work focuses on ensuring the safety and efficacy of new medical and surgical interventions through rigorous preclinical testing.